Risk factors associated with cognitive dysfunction in patients on peritoneal dialysis
COGNITIVE DYSFUNCTION
Abstract
Introduction: Cognitive impairments represent a significant global issue, as they deteriorate patients' quality of life, increase mortality and the number of hospitalizations, burden the healthcare system, and raise treatment costs. Aim of procedure: The aim of this research is to determine the prevalence of cognitive dysfunction in patients undergoing peritoneal dialysis. Material and Methods: A cross-sectional study was conducted in May 2024, at the University Clinical Center of Vojvodina, at the Clinic for <nephrology and clinical immunology. The study included 30 patients undergoing peritoneal dialysis. The Montreal Cognitive Assessment (MoCA) was used as the instrument for assessing cognitive dysfunction. The maximum score is 30, and a result of <25 was considered indicative of cognitive dysfunction. Results: Of the 30 patients, 55.2% were male. The most represented age category was ≥60 years, comprising 43.5%. Among comorbidities, hypertension was the most prevalent at 33.3%. Cognitive dysfunction was confirmed in 34% of the patients. A logistic regression model was applied to identify predictors of cognitive dysfunction, revealing that female patients and those over 60 years of age were at a higher risk for cognitive dysfunction. A positive correlation between the MMSE score and the total dialysis adequacy index Kt/V was also identified. Conclusion: Significant predictors of cognitive dysfunction in patients on peritoneal dialysis were female gender, age category (above 60 years), glucose levels, daily and weekly doses of vitamin D, and the dialysis adequacy index Kt/V.
Key words: cognitive dysfunction, peritoneal dialysis, risk factors
References
2. Andreoli MC, Totoli C. Peritoneal dialysis. Revista da Assosiacao Medica Braileira. 2020;66(1):37-44.
3. Kovačević Z,Cvetković O, Janićijević K, Janjićijević-Petrović M, Cvetković M,Zornić N. Clinical analysis of peritonitis in peritoneal dialysis patients. Srpski arhiv za celokupno lekarstvo. 2021;149(5-6):282-7.
4. Baralić M. Strukturne i funkcionalne promene fibrinogena kod bolesnika na pritoneumskoj dijalizi (doktorska disertacija). Beograd: Medicinski fakultet;2022.
5. Bozhilov K, Vo KB, Wong LL. Can the timed up & go test and montreal cognitive assessment predict outcomes in patients waitlisted for renal transplant? Clin Transpl. 2021; 35(1):e14161.
6. Fang W, Ni Z, Qian J. Key Factors for a High-Quality Peritoneal Dialysis Program- The role of the PD Team and Continuous Quality Improvement. Perit Dial Int. 2014;34(2):S35-S42.
7. El, Gohary IE El, Sheshtawi HA, Mohamed MMA. Cognitive disorders in chronic kidney disease and hemodialysis patients. J Egypt Soc Nephrol Transplant. 2018;18(4):130.
8. Gesualdo GD, Duarte JG, Zazzetta MS, Kusumota L, Say KG, Pavarini SCI, et al. Cognitive impairment of patients with chronic renal disease on hemodialysis and its relationship with sociodemographic and clinical characteristics. Dement Neuropsychol. 2017; 11(3):221–6.
9. Tian X, Guo X, Xia X, Yu H, Li X, Jiang A, et al. The comparison of cognitive function and risk of dementia in CKD patients under peritoneal dialysis and hemodialysis: A PRISMA-compliant systematic review and meta-analysis. Medicine (United States). Lippincott Williams and Wilkins. 2019.
10. Goleniaa A, Żołek N, Olejnikc P, Wojtaszekd E, Glogowski T, Malyszko J. Prevalence of Cognitive Impairmentin Peritoneal Dialysis Patients and Associated Factors. Kidney Blood Press Res. 2023;48:202–208.
11. McAdams-Demarco MA, Daubresse M, Bae S, Gross AL, Carlson MC, Segev DL. Dementia, Alzheimer’s disease, and mortality after hemodialysis initiation. Clin J Am Soc Nephrol. 2018 ;13(9):1339–47.
12. Zhu B, Jin LN, Shen JQ, Liu JF, Jiang RY, Yang L, et al. Differential expression of serum biomarkers in hemodialysis patients with mild cognitive decline: A prospective single-center cohort study. Sci Rep. 2018;8(1):12250.
13. Shea YF, Lee MSC, Mok MYM, Chan FHW, Chan TM. Prevalence of cognitive impairment among peritoneal dialysis patients: a systematic review and meta-analysis. Clin Exp Nephrol. 2019;23(10):1221–34.
14. Wu C, Yu R, Li Q, Chen J, Wang W. Exploring the impact of cognitive impairments on treatment compliance and quality of life in patients with Continuous Ambulatory Peritoneal Dialysis (CAPD). Medicine 2023;102:43.
15. Brás C, Marques J, Alves P, Fernandes V and Ferreira A. "MO691: Risk Factors Associated with Cognitive Dysfunction in Peritoneal Dialysis."Nephrology Dialysis Transplantation 37.Supplement_3 (2022): gfac078-028.
16. Karakizlis H, Thiele S, Greene B, Hoyer J. "Cognitive performance in dialysis patients-" when is the right time to test?"." BMC nephrology.2021;205.
17. Neumann D, Mau W, Wienke A, Girndt M. Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one-year course. Kidney Int. 2018;93(2): 430–8.
18. Liao JL, Xiong ZY, Yang ZK et al. An association of cognitive impairment with diabetes and retinopathy in end stage renal disease patients under peritoneal dialysis. PloS One. 2017;12:e0183965.
19. Zhang YH, Yang ZK, Wang JW, Xiong ZY, Liao JL, Hao L, et al. Cognitive changes in peritoneal dialysis patients: a multicenter prospective cohort study. Am J Kidney Dis 2018;72:691-700.